Program snapshot in one minute

• Describe your program in one sentence, including therapy class, autologous or allogeneic, and current clinical phase
• Which patient population and dosing schedule are you designing manufacturing around Options: Single-dose autologous per patient, Multiple doses per patient, Allogeneic pooled-batch dosing, Other
• When do you need GMP supply available for the first clinical dosing event Options: Within 4 weeks, Within 8 weeks, 1-3 months, 3-6 months, 6+ months
• Estimate your target batch volume or number of patients to be supported per month during the first 12 months Options: 1-5 patients/month, 6-15 patients/month, 16-50 patients/month, 50+ patients/month, Not yet defined
• List the internal roles that will own program decisions, technical transfer, and quality sign-off
• Describe the current state of your process documents and release specifications, for example, SOPs, batch record templates, and validated assays

Where schedule and reality diverge

• What single schedule risk would force your team to delay first-in-human dosing
• Walk me through the last time a manufacturing delay moved a clinical milestone, what failed and how long the program slipped
• Which steps in your current transfer and scale-up path show the highest variability in outcome or timing Options: Leukapheresis receipt and acceptance, Upstream expansion and transduction, Downstream harvesting and formulation, Analytical testing turnaround, Batch documentation review
• How many months of program runway do you have before a missed dose would trigger a regulatory filing or funding consequence Options: <1 month, 1-3 months, 3-6 months, >6 months
• If a single upstream failure occurred during a pilot run, what organizational outcome would make you stop engaging an external manufacturer

What technical issues keep you up at work

• If your potency assay drifted by 20 percent after a transfer, would your team proceed on the same release criteria or pause to investigate Options: Proceed with investigation in parallel, Pause production until resolved, Adjust acceptance criteria temporarily, Unsure
• List the critical quality attributes you track today and the target ranges for each
• Which in-process analytics or controls do you currently lack that would reduce batch failure risk Options: Real-time viability monitoring, Potency at-line assay, Closed system sampling, Environmental trend analytics, Other
• Tell us about any comparability or scale-up risks you expect when moving from your current equipment to a contract facility
• What single analytical gap would make it impossible for your quality team to accept pilot batches

Who moves the levers internally

• Who in your organization can unilaterally stop a vendor engagement and what conditions would trigger that action
• Describe the cross-functional review points and required sign-offs from quality, regulatory, and procurement during tech transfer
• How quickly do reviewers typically turn around comments on batch records, validation documents, or assay reports Options: <48 hours, 3-5 business days, 1-2 weeks, Longer than 2 weeks
• Which external stakeholders, such as CROs, clinical sites, or supply partners, must be looped into manufacturing changes
• If procurement or legal insists on a contractual clause you cannot accept, do you have a named technical champion who can escalate to keep timelines Options: Yes, named champion and authority, Champion exists but limited authority, No technical champion available, Unsure

The other options you're weighing

• What would have to break in your current approach for you to switch vendors within the next quarter
• Which alternatives are you actively evaluating Options: Existing CDMO partner, In-house scale-up, Academic GMP facility, New CDMO entrants, Regional contract labs, Other
• For any incumbent partner you currently use, which performance metrics meet your needs and which fall short
• Has anyone on your team proposed handling GMP manufacturing internally instead of contracting it out Options: Yes, actively pursuing, Proposed but not resourced, No internal proposal, Unsure
• What would have to be true of an internal manufacturing option for you to prefer it over an external partner this year

Readiness facts that decide feasibility

• If you cannot provide release-ready analytical methods and material transfer paperwork within four weeks, can you still meet your regulatory timeline Options: Yes, timeline preserved, No, timeline at risk, Maybe with parallel work, Unsure
• Which of these prerequisites are already in place for an external transfer Options: MTAs and IP agreements, Master cell bank and vials available, Validated release assays, Quality management system access, Supply chain for critical raw materials, Regulatory filings in progress, Dedicated program funding
• Who owns the chain of custody for patient or donor material and can sign transfer documents
• Estimate the full time equivalents you can dedicate to tech transfer and pilot support for the first 3 months Options: <1 FTE, 1-2 FTEs, 3-5 FTEs, 5+ FTEs, Not sure
• Which regulatory approvals or committee clearances are gating your ability to ship material across regions Options: No extra approvals required, Local ethics or IRB, Import/export permits, Regulatory agency pre-approval, Other
• Is there any contractual or IP restriction that would prevent transfer of your manufacturing protocol to an external facility Options: Yes, transfer prohibited, Yes, transferable with license, No restrictions, Unsure, need legal review

How you will judge a successful pilot

• If the pilot achieves target yield but misses potency, would you accept additional optimization runs or require a full restart Options: Accept optimizations and continue, Require full restart, Accept with adjusted criteria, Decision depends on magnitude of miss
• Which acceptance criteria must the pilot meet to be considered successful Options: Viability, Cell yield, Potency assay, Identity, Purity, Sterility, Endotoxin, Comparability to reference, Documentation completeness
• Provide target numeric ranges for up to three highest-priority acceptance metrics, for example viability > 70%
• Name the roles that must sign off on pilot batch release within your organization
• If the pilot misses an acceptance criterion by less than 10 percent, what escalation path do you expect and who decides
• If the pilot meets every acceptance criterion, what internal approvals would be required for you to contract commercial runs and what is the shortest realistic timeline Options: Immediate commercial contracting within 2 weeks, 1 month, 1-3 months, Longer than 3 months

Budget, procurement, and commercial gates

• What single budget constraint could pause contracting for manufacturing despite a successful pilot
• What is the current budget status for outsourced manufacturing Options: Budget approved and allocated, Budget approved but not allocated, Budget requested, pending approval, No budget yet, Funded by milestone or grant
• How does a unit cost above your target change your projected patients dosed in year one, in percentage terms or absolute patients
• List the roles that must approve vendor contracts and the typical procurement lead time
• If contract signature slips past your target launch date, what commercial consequence would follow, for example missed enrollment or additional bridging studies
• Is an approved purchase order or signed budget a gating requirement before the seller begins tech transfer activities Options: Yes, PO required, Signed budget sufficient, Partial funding acceptable, Case by case

Clear next steps that accelerate the decision

• Identify the one internal milestone that, if hit, would make you ready to sign a statement of work within 30 days
• Which deliverables or documents do you need from the seller to complete your internal technical and quality review Options: Process flow diagram, Draft batch record, Validation plan, Analytical method descriptions, Risk assessment
• Preferred timeline to start tech transfer after contract signature Options: Immediate (within 2 weeks), Within 1 month, 1-2 months, 3+ months, Depends on material readiness
• Provide the role and preferred contact method for the primary point of contact for scheduling pilot runs and receiving batch reports
• If the pilot confirms feasibility, what timeline would trigger you to execute a commercial statement of work Options: Within 2 weeks, Within 1 month, 1-3 months, Longer than 3 months
• What would cause you to decline this manufacturing approach even after a successful pilot

• Solution Experience Session: Proposed Manufacturing Approach & Transfer Plan

• Confirm the current state and its cost to your program
• You confirm the proposed manufacturing approach directly addresses the batch failure and product-characteristics risks you described.
• Deliver a detailed technology-transfer plan including responsibilities, milestone dates, pilot run parameters, and defined acceptance criteria.
• Present the proposed manufacturing approach tied to your program goals
• You agree on a technology-transfer plan with clear milestones, responsibilities, and acceptance criteria sufficient to run a pilot using your cell line.
• Provide the most recent process characterization data, analytical assay results, and your target acceptance thresholds for yield, purity, and potency.
• Walk through the technology-transfer plan and pilot run design
• Deliver a short risk analysis listing the top five process failure modes for your program and proposed mitigations tied to the transfer plan.
• You and the seller agree on the concrete evidence and pilot parameters required before moving to Pilot Evaluation.
• Agree on the pilot run window and sample transfer schedule to enable the pilot evaluation within the agreed timeline.
• Show the success signals and acceptance evidence
• Validate alignment with your requirements
• Agree on remaining evidence and next steps toward Pilot Evaluation

• Solution Experience Session
• Solution Experience Deck
• Solution Brief

• meeting
• slides
• document

• Clinical-Scale GMP Manufacturing (per batch)
• Commercial-Scale GMP Manufacturing (per batch)
• Technology Transfer Execution (process migration)
• Process Development and Optimization Runs
• Engineering and Scale-Up Qualification Runs
• Analytical Method Transfer and Release Testing
• Raw Material and Reagent GMP Sourcing and Qualification
• Aseptic Fill, Formulation, and Cryostorage Packaging
• Batch Release Documentation and Regulatory Lot Dossier
• Environmental Monitoring and Cleanroom Control Operations
• Operator Training and On‑Site Process Transfer Support
• Deviation Investigation and CAPA Execution (per event)
• Comparability Studies Following Process Transfer
• Supply Chain Cold-Chain Shipping and Chain-of-Custody
• Stability and Cryopreservation Lot Qualification

Clinical-Scale GMP Manufacturing (per batch)

• What is the target release cell count and viable cell viability for a clinical-scale batch (specify cells per final bag or dose)?
• Which master batch record (MBR) or standard operating procedure (SOP) version will we follow for the initial clinical run? Options: You will supply an existing MBR/SOP, We will adapt our baseline MBR/SOP, Joint development during transfer
• Do you require closed-system processing (for example closed automated cell processing unit) or open cleanroom manipulations for the clinical batch? Options: Closed system only, Open cleanroom allowed with defined mitigations, Either, to be decided
• How many manufacturing days and scheduled shift coverage are needed for a single clinical batch run (include set-up, processing, and quench/harvest time)? Options: 1 day, 2-3 days, 4+ days
• Who will provide the starting cellular material and documentation for chain of identity and donor screening (for autologous: apheresis kit ID; for allogeneic: MCB/WCB CoA)?

Commercial-Scale GMP Manufacturing (per batch)

• Which target commercial batch size do you expect (cells per batch or number of patient doses per batch)? Options: Specify target cells per batch, Specify doses per batch, Undecided / need scale study
• Do you require single-site commercial manufacturing or multi-site parallel runs for capacity redundancy? Options: Single site, Multi-site parallel, Phased ramp to multi-site
• Provide the target throughput timeline and launch month for first commercial batch so we can map qualification and supply ramp milestones.
• Which closed system or bioreactor platform (equipment ID or class) must be used at commercial scale to match process performance?
• Are there commercial stability or shelf-life targets (for example X days at -80C or Y months at LN2) that will drive formulation and cryostorage packaging choices? Options: Yes, specify target, No target yet, We need to establish during qualification

Technology Transfer Execution (process migration)

• Describe the source process artifacts you will deliver for transfer: process flow diagram, critical process parameters (CPPs), critical quality attributes (CQAs), and batch records.
• How many hands-on days of on-site transfer support do you expect for knowledge transfer of critical manual manipulations? Options: 0-3 days, 4-7 days, 8+ days
• Which assays and acceptance ranges from your current data (for example transduction efficiency %, potency assay thresholds) must be demonstrated equivalently after migration?
• Who will own the final approved process change control (provide role or title responsible for process sign-off)?
• Specify any intellectual property or data handling constraints for process materials and analytics (for example redaction of proprietary vector sequences or restricted assay SOP access).

Process Development and Optimization Runs

• Which specific process attributes do you want optimized (for example transduction multiplicity of infection, expansion fold, viability at harvest)?
• Provide target improvement metrics you are seeking from development runs, such as X% increase in yield or Y% reduction in culture time.
• How many process development runs do you expect in scope before locking the process for qualification? Options: 1-2 runs, 3-4 runs, 5+ runs
• Do you require parallel analytical development (for example development of a potency assay) during optimization runs? Options: Yes, No, Partially — existing assays only
• Which in-process sampling points and assays (for example viability, phenotype markers, transduction %) must be included in each optimization run?

Engineering and Scale-Up Qualification Runs

• How many engineering qualification runs are required to demonstrate scale reproducibility at your target commercial batch size? Options: 1 run, 2 runs, 3+ runs
• Which equipment qualification documents must be delivered with each run (for example installation qualification IQ, operational qualification OQ, performance qualification PQ)? Options: IQ/OQ/PQ required, OQ/PQ only, PQ only
• Specify the critical process parameter ranges to be challenged during qualification (for example agitation speed, gas flow, temperature limits).
• Who will approve deviations discovered during qualification runs and which documented evidence do you require for approval (for example investigation report and trending data)?
• Indicate required environmental and utility monitoring tied to scale-up (for example CO2, temperature excursions, particle counts during PQ runs).

Analytical Method Transfer and Release Testing

• Which release assays must be transferred and validated in our lab (for example sterility per USP <71>, mycoplasma PCR, endotoxin, potency assay, flow cytometry panel)?
• Specify the acceptance criteria or release ranges for each assay to be used for lot release.
• Do you require full method validation or partial validation/verification for each assay based on prior data? Options: Full validation, Partial validation/verification, Verification only
• Provide the reference method SOPs, calibration standards, and control materials you will supply for method transfer.
• How will you provide archived assay qualification data and historical CoA (certificate of analysis) reports to support transfer? Options: Electronic files via secure transfer, Paper records provided on-site, Combination

Raw Material and Reagent GMP Sourcing and Qualification

• List the critical raw materials that require GMP grade sourcing (for example cytokines, viral vectors, media components, cryoprotectant).
• Which vendor qualification documents do you require for each material (for example CoA, supplier audit report, GMP certificate)?
• Do you have preferred suppliers or approved vendor lists we must use for any material class? Options: Yes, we will provide preferred suppliers, No, open sourcing allowed, Preferred but open to alternatives
• How many lots of each critical raw material must be qualified before release to production (for example two lots for media)? Options: 1 lot, 2 lots, 3+ lots
• Specify required storage conditions and shelf-life expectations for each reagent that will affect receiving and stock rotation (for example -20C, 2-8C, LN2).

Aseptic Fill, Formulation, and Cryostorage Packaging

• Which final container and closure system must be used for product dosing (for example cryobag model, vial type, septum material)?
• Do you require lyophilized, liquid, or frozen formulation and which excipients must be present in the formulation (list excipients and concentrations)?
• How many fill lines and aseptic operators are required per batch to meet your timeline? Options: 1 fill line, 2 fill lines, 3+ fill lines
• Provide cooling and cryostorage targets for packaging and kitting (for example -80C hold time, LN2 vapor requirement, transfer-to-shipping timeline).
• Are there specific container closure integrity (CCI) or endotoxin limits you require for final packaged product? Options: Yes, specify limits, No specific limits beyond release assays, TBD during qualification

Batch Release Documentation and Regulatory Lot Dossier

• What documents must be included in the lot dossier for release to clinic or market (for example final batch record, CoA, environmental monitoring summary, chain-of-custody manifest)?
• Which regulatory submission standard must the dossier conform to (for example IND module format, BLA lot dossier expectations, EMA QP requirements)? Options: IND-format dossier, BLA-format dossier, EMA/ICH format, Other
• What naming and document control conventions must be used for the lot dossier and batch records (for example document IDs, revision numbering)?
• How will final sign-off be authorized for lot release and which titles must appear on the release signatures (for example qualified person QP, head of quality)?
• What specific evidence will validate lot release for the first clinical/commercial batch (for example passing sterility, potency above X, CoA attached)?

Environmental Monitoring and Cleanroom Control Operations

• Which cleanroom classification and particle/viable limits apply to your process steps (for example ISO 5 filling with defined particle counts and settle plate limits)?
• How often do you require viable and non-viable monitoring during a production campaign (for example continuous particle monitoring, hourly viable air sampling)? Options: Continuous non-viable + periodic viable samples, Periodic only, Custom schedule
• Provide required trending and reporting formats for environmental data that must accompany batch records (for example weekly EM trend charts, alarm logs).
• Are there specific excursion thresholds that mandate automatic batch hold and investigation (for example particle counts > X, settle plate CFU > Y)? Options: Yes — specify thresholds, No — use standard limits, Define during qualification
• Who will be responsible for corrective actions and notification for environmental deviations during a run (provide role or title)?

Operator Training and On‑Site Process Transfer Support

• How many operator trainees do you expect to have on-site for process transfer and what are their baseline qualifications (for example GMP experience, flow cytometry competency)?
• Which training artifacts are required before operators can execute GMP runs (for example training matrix, competency checklist, observed practice sign-off)?
• Do you require documented operator shadowing hours and sign-off per SOP before independent execution? Options: Yes — specify hours, No — competency-based sign-off, Hybrid
• Provide any occupational health or PPE restrictions that will affect operator scheduling and headcount during sterile operations.
• How will you supply training records and operator identity proofing for file inclusion (for example electronic training files, scanned certificates)? Options: Electronic upload, On-site provision, Combination

Deviation Investigation and CAPA Execution (per event)

• What deviation severity classification do you require (for example minor/major/critical) and how should each map to CAPA timelines?
• Which root cause analysis methods do you prefer for investigations (for example 5 Whys, fishbone, fault tree) and must they be documented in a specific template? Options: 5 Whys, Fishbone, Fault tree, No preference
• How quickly must initial containment and a preliminary investigation report be provided after an excursion (for example within 24 hours)? Options: Within 24 hours, 48 hours, 72 hours
• Who approves corrective actions and how is effectiveness monitored (for example defined metrics over N production runs)?
• Do you require post-CAPA verification sampling or additional release testing for impacted batches? Options: Yes, No, Case-by-case

• decision_readiness
• current_state
• gaps
• stakeholders
• desired_state
• success_criteria
• desired_state
• success_criteria
• stakeholders
• gaps
• current_state
• decision_readiness
• stakeholders
• decision_readiness
• current_state
• decision_readiness
• decision_readiness
• decision_readiness
• decision_readiness

• Master Services Agreement (MSA)
• Statement of Work (SOW)
• Manufacturing and Supply Agreement
• Quality Agreement (GMP) - required if buyer is subject to clinical or commercial GMP obligations
• Technology Transfer & IP Addendum
• Pricing & Payment Schedule
• Regulatory Support Addendum
• Change Order Agreement
• Transition & Termination Plan

• Go-live Health Check (weeks 1-4)
• First KPI Review (weeks 4-10)
• 90-Day Operational Review (around day 90)
• Quarterly Success Review (ongoing)

• Schedule the next quarter's working sessions for critical improvement items and training deliveries.
• Deliver a data pack of raw batch records and QC summaries to support the agreed root-cause analysis.
• Update SOPs or operator checklists for any procedural fixes identified in the root-cause analysis.
• Summary of outcomes vs targets
• Confirm whether the program is operationally stable against batch success rate and deviation targets recorded in Pilot Evaluation.
• Ensure all high-severity deviations have CAPAs with owners and realistic completion dates.
• Agree capacity mitigations to prevent schedule slippage and ensure reserved capacity utilization stays within the agreed band.
• Publish a CAPA closure plan for all high-severity deviations with target completion dates.
• Adjust the master production schedule to reflect committed reserved capacity and identify contingency slots.
• Launch a targeted operator training session on any process steps linked to recurring deviations.
• Quarter summary for named metrics
• Maintain or improve the on-time batch completion rate and average days to batch release toward targets recorded in Pilot Evaluation.
• Drive closure of the quality and change request backlog on a defined schedule.
• Agree the next quarter's top operational priorities and the metrics that will show progress.
• Assign owners and target dates for outstanding change requests and deviations needing remediation.
• Publish the quarterly performance pack including raw KPI data and deviation summaries for stakeholder review.
• Re-confirm success criteria and owners
• All operational owners and escalation contacts confirmed for production, QA release, and material logistics.
• Critical open issues logged with immediate remediation actions and completion dates.
• Data sources and cadence for the first KPI review identified and validated.
• Document and circulate the list of confirmed owners and escalation contacts for production and QA release.
• Record and circulate the critical blockers register and remediation tasks with due dates.
• Validate and confirm the sources and format of operational data that will feed the first KPI review.
• Present first-run outcome data
• Establish whether batch success rate and average days to batch release are on-track toward the targets recorded in Pilot Evaluation.
• Document root causes for any shortfalls and agree corrective actions with completion dates.
• Confirm the measurement cadence and required data for the 90-day operational review.
• Create a corrective action plan for each KPI gap with specific tasks and target close dates.
• Quality deviations and CAPA status
• Open quality and change request review
• Deployment and access validation
• Review schedule adherence and capacity signals
• Capacity and scheduling review
• Early operations signals
• Continuous-improvement backlog progress
• Root cause analysis for gaps
• Risk register and regulatory considerations
• Continuous-improvement actions
• Open issues and blockers
• Agree corrective actions and timelines
• Confirm path to acceptance checkpoint
• Close-loop and next steps
• Priorities and commitments for next quarter
• Agree immediate remediation actions